Investing in Biotech

Randal Kirk, one of the only billionaires to make his money from investing in biotech, says his new synthetic biology company, Intrexon, will be the biggest thing he has ever done, says Forbes' Robert Langreth and Matthew Herper. The company is working on protein-based drugs, gene therapy, industrial enzymes, and ag-bio.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.